COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Corticosteroid Prophylaxis on the Cardiopulmonary Bypass-Induced Systemic Inflammatory Response

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01296074
Recruitment Status : Completed
First Posted : February 15, 2011
Last Update Posted : October 19, 2017
National Natural Science Foundation of China
Information provided by (Responsible Party):
Xiaotong Hou, Beijing Anzhen Hospital

Brief Summary:
To observe the effect of glucocorticoid on the dynamic changes of monocyte subsets in the peripheral blood of valve disease patients undergoing cardiopulmonary bypass perioperatively.

Condition or disease Intervention/treatment Phase
Heart Valve Diseases Systemic Inflammatory Response Syndrome Drug: Corticosteroid Not Applicable

Detailed Description:

Systemic inflammatory response syndrome (SIRS) is a common major complication of cardiopulmonary bypass. "Emergency Hematopoiesis" is the pathological process induced by the inflammation. The investigators previously confirmed that emergency hematopoiesis induced by cardiopulmonary bypass led to dynamic changes of quantities of monocyte subsets, there is a significant increase in the number of two monocyte subsets: 1) CD14highCD16+ monocyte with strong immunomodulatory activity; 2) CD14lowCD16- monocyte with potential ability of proliferation and differentiation. Therefore, a new hypothesis risen: "the change of the function and the number of monocyte subsets induced by emergency hematopoiesis play an important role for SIRS occurrence after cardiopulmonary bypass, correcting emergency hematopoiesis is a new breakthrough in the prevention and treatment of SIRS." To identify the mechanism of function changed in different monocyte subsets during the pathogenesis of SIRS, the research intended to target perioperative-period patients with heart valve replacement, monitor dynamically the number and phenotype of peripheral blood monocyte subsets by flow cytometry; sort out of different monocyte subsets for cell culture in vitro, observe the ability of proliferation and differentiation and effects between monocyte subsets and T lymphocyte; investigate the mechanism of immune function changes with antibody-blocking and compartment culture in patients; observe the impact of glucocorticoid treatment on the emergency hematopoiesis, offer new objects for evaluation of immune status in patients and provide new evidence for anti-inflammatory therapy .

Patients should be follow the protocol of cardiopulmonary bypass according to normal hospital routine practice.

A total of 30 patients will be enrolled in this clinical trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: The Perioperative Effect of Corticosteroid Prophylaxis on the Cardiopulmonary Bypass-Induced Systemic Inflammatory Response
Actual Study Start Date : March 2011
Actual Primary Completion Date : April 2011
Actual Study Completion Date : August 2011

Arm Intervention/treatment
Experimental: Corticosteroid
Methylprednisolone will be given during cardiopulmonary bypass.
Drug: Corticosteroid
500mg Methylprednisolone will be in the priming of cardiopulmonary bypass.
Other Name: Solu-Medrol

Primary Outcome Measures :
  1. recovery of monocyte subsets [ Time Frame: baseline, day1, 3, 5, 7 postoperative ]
    Changes in monocyte subsets in cardiopulmonary bypass patients were found.After 1w-2w postoperatively, it would recover to the preoperative level.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Valve replacement under cardiopulmonary bypass

Exclusion Criteria:

  • Cardiopulmonary bypass time over 120 minutes
  • Hyperlipidemia
  • Diabetes mellitus
  • Autoimmune diseases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01296074

Layout table for location information
China, Beijing
Xiaotong Hou
Beijing, Beijing, China, 100029
Sponsors and Collaborators
Beijing Anzhen Hospital
National Natural Science Foundation of China
Layout table for investigator information
Principal Investigator: Xiaotong Hou, M.D., Ph.D. Beijing Anzhen Hospital
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Xiaotong Hou, Chief of Center for Cardiac Intensive Care, Beijing Anzhen Hospital Identifier: NCT01296074    
Other Study ID Numbers: 81070203
First Posted: February 15, 2011    Key Record Dates
Last Update Posted: October 19, 2017
Last Verified: October 2017
Keywords provided by Xiaotong Hou, Beijing Anzhen Hospital:
cardiopulmonary bypass
cardiac surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Valve Diseases
Systemic Inflammatory Response Syndrome
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Methylprednisolone Hemisuccinate
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Neuroprotective Agents
Protective Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents